Cargando…
Horizons in cancer research. Volume 49 /
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Hauppauge, N.Y. : Lancaster :
Nova Science ; Gazelle [distributor],
2012.
|
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- HORIZONS IN CANCER RESEARCH. VOLUME 49 ; HORIZONS IN CANCER RESEARCH. VOLUME 49 ; Contents ; Preface; Endometrial Cancer: Diagnosis, Treatment and Prevention; Abstract; 1. Introduction; 2. Diagnosis of Endometrial Cancer; Symptoms and Screening; 3. Biomarkers Associated with Endometrial Cancer; 3.1. Oncogenes; 3.2. Tumour Suppressor Genes; 3.3. Microsatellite Instability (MSI); 3.4. MiroRNA; 3.5. Invasion and Migration; 3.6. Angiogenesis; 3.7. Endogenous Hormones and Endometrial Cancer; Steroid Hormones; Leptin and Adiponectin; Insulin, IGFs and SHBG; Growth Hormone Axis.
- 3.8. Inflammatory MarkersCytokines; 4. Treatments; 4.1. Primary Surgery; 4.2. Adjuvant Treatments; 4.3. Novel Pathways and Targeted Therapies; Inhibiting Pathways of PI3-AKT-mTOR; EGFR Inhibitor and HER Family Inhibition; Antiangiogenics Agents; Cancer Stem Cells; 5. Prevention; Diet; Physical Activity; Conclusion; Acknowledgments; References; Liver Metastases of Colorectal Carcinoma: Magnetic Resonance Imaging Techniques and New Developments; Abstract; Introduction; Imaging; US, CT, PET(/CT); Magnetic Resonance Imaging; New Developments in MRI; Sequences for the Liver.
- 1. Diffusion-Weighted Imaging (DWI)(Single Shot Spin Echo Echo Planar Imaging (SS SE-EPI Sequence))2. T1w Dynamic Contrast-Enhanced (DCE) MRI (4D THRIVE); Analysis of Tumour Heterogeneity: Region-of-Interest (ROI) Placements Versus Parametric (Pixel) Mapping; Magnetic Resonance Imaging Characteristics of "Hypovascular" Colorectal Liver Metastases; Usefulness of High B-Value DWI in Clinical Practice; Usefulness of DCE MRI in Clinical Practice; Conclusion; References; Can We Develop More Effective Combination Antiangiogenic Therapy for Patients with Cancer?; Abstract; Introduction.
- Clinical Trials with Antiangiogenic Agents in HCC, Net, and RCC (Table I)Hepatocellular Carcinoma (HCC); Bevacizumab; Sunitinib; Sorafenib; Neuroendocrine Tumors (NET); Bevacizumab; Sunitinib; Renal Cell Carcinoma (RCC); Bevacizumab; Sunitinib; Sorafenib; Pazopanib; Other Antiangiogenic Agents; Mechanism of Resistance to Antiangiogenic Therapy; Rationale for Development of More Effective Antiangiogenic Therapy (Table II and Figure 1) ; References; Lung Metastases: Etiology, and Treatment; 1. Etiology; 1.1. Epithelial Tumors; Colorrectal Cancer; Breast Cancer; Gynaecological Cancer.
- Renal CarcinomaMelanoma; Hepatocelular Carcinoma (HCC); Head and Neck Cancer; 1.2. Sarcomas; Osteosarcoma; Soft Tissue; 1.3. Germ Cell Tumors; 2. Prognostic Factors; 2.1. The Number of Pulmonary Metastases; Influence of the Number of Metastases on Survival; 2.2. Thoracic Lymphatic Involvement; What Is the True Incidence of Thoracic; Lymph Node Involvement?; What Is the Impact on Survival for Patients in Whom Pulmonary Metastases Have Themselves Metastasized to Lymph Nodes?; What Is Current Practice of Lymph Node; Assessment and Dissection?; 2.3. Special Primary Malignancies; Breast Cancer.